Home » Stocks » RAPT

Rapt Therapeutics, Inc. (RAPT)

Stock Price: $20.87 USD -0.30 (-1.42%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 518.99M
Revenue (ttm) 5.04M
Net Income (ttm) -52.89M
Shares Out 24.13M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $20.87
Previous Close $21.17
Change ($) -0.30
Change (%) -1.42%
Day's Open 21.35
Day's Range 20.28 - 21.49
Day's Volume 131,655
52-Week Range 13.36 - 41.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.

6 days ago - Zacks Investment Research

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of 3.70% and -36.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

-Evidence of Monotherapy and Combination Activity in Charged Tumor Types--Company Advances Several Cohorts into Phase 2 Expansions--Conference Call and Webcast to be Held at 8:30 a.m. ET Today-

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and...

6 months ago - GlobeNewsWire

RAPT Therapeutics (RAPT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing a...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing a...

8 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in RAPT Therapeutics.

9 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

10 months ago - GlobeNewsWire

Preclinical and Healthy Volunteer Data Show Promise of RPT193 to Block Th2 Cells in Allergic Inflammatory Disease Preclinical and Healthy Volunteer Data Show Promise of RPT193 to Block Th2 Cells in Alle...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing an...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing a...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing an...

1 year ago - GlobeNewsWire

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, APRE, BNTX, GKOS, INMD, KRTX, NXTC ...
1 year ago - The Motley Fool

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193... [Read more...]

Industry
Biotechnology
IPO Date
Oct 31, 2019
CEO
Brian Wong
Employees
68
Stock Exchange
NASDAQ
Ticker Symbol
RAPT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price forecast is 36.50, which is an increase of 74.89% from the latest price.

Price Target
$36.50
(74.89% upside)
Analyst Consensus: Buy